Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
The latest announcement is out from Bioxyne Limited ( (AU:BXN) ).
Bioxyne Limited, through its subsidiary Breathe Life Sciences, has received GMP compliance certificates under Mutual Recognition Agreements with several countries, including the UK, Canada, and the EU. This certification supports Bioxyne’s strategy to expand its global presence, particularly in European markets, and positions the company for growth in FY2026 as it enters new high-growth markets such as the UK and Germany.
More about Bioxyne Limited
Bioxyne Limited is an Australian pharmaceutical company that specializes in the development and commercialization of innovative medicines and active pharmaceutical ingredients. Through its subsidiary, Breathe Life Sciences, the company is a leading manufacturer and distributor of controlled substances, including medicinal cannabis, Psilocybin, and MDMA. With operations in Australia, Japan, the UK, and Czechia, Bioxyne focuses on alternative therapeutics and investigational medicines, and is recognized for its Dr Watson® brand of cannabis-based products.
Average Trading Volume: 3,380,342
Technical Sentiment Signal: Buy
Current Market Cap: A$58.45M
See more insights into BXN stock on TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue